Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Luciana Griebel

Luciana Griebel

London +44 20 7067 2268 lgriebel@cov.com Download V-card

Luciana Griebel has a broad corporate practice, primarily focusing on mergers and acquisitions, private equity and venture capital transactions. Ms. Griebel also advises on corporate restructurings, capital markets transactions, strategic investments and corporate governance matters.

Ms. Griebel acts for companies at all stages of development, as well as investors and management teams. Her experience covers a wide range of industries, in particular the life sciences, branded goods and technology sectors. Ms Griebel utilizes her technical knowledge and extensive deal experience to provide practical, commercial solutions to clients.

  • Merck in its €2.1 billion acquisition of Antelliq Group, a leader in digital animal identification, traceability and monitoring solutions, the fastest growing part of the animal health industry.
  • AstraZeneca in connection with its strategic oncology collaboration with Innate Pharma S.A., including with respect to its acquisition of a nine percent interest in Innate Pharma.
  • Johnson & Johnson in the sale of the global rights to Compeed® to HRA Pharma.
  • Johnson & Johnson in the sale of its portfolio of OTC anti-fungal products (Pevaryl®, Fungoral®, Gyno-Pevaryl® and Epi-Pevaryl®) in certain European countries, to Trimb Healthcare AB.
  • BenevolentAI on an £80 million equity investment by new and existing investors, including Woodford Investment Management, at a pre-money valuation of £1.4 billion.
  • Central European Media Enterprises Ltd., a company listed on NASDAQ and the Prague Stock Exchange, in the $262.2 million sale of its broadcast operations in Croatia (“Nova TV”) and in Slovenia (“POP TV”) to a subsidiary of United Group B.V, a private company which is majority owned by U.S. investment firm KKR.
  • The management team on The Foundry’s investment from HgCapital under the terms of which HgCapital assumed majority ownership from The Carlyle Group for an enterprise value of £200 million ($312 million USD). The Foundry is a leading provider of award-winning creative software.
  • Qualcomm Inc. on its £1.56 billion recommended cash offer for CSR plc.
  • Peel Hunt LLP, in its role as nominated adviser, in connection with two separate placings by Motif Bio plc, a company with securities admitted to trading on AIM.
  • ReNeuron Group plc, a leading clinical stage stem cell therapy company, on a £68.4 million follow-on financing.
  • Atopix Therapeutics Limited on its sale to Chiesi Farmaceutici S.p.A.
  • Johnson & Johnson on the acquisition of XO1 Limited, an asset-centric biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.
  • A syndicate of investors, including Imperial Innovations, Johnson & Johnson Innovation – JJDC, Inc., Cambridge Innovation Capital and Woodford Patient Capital Trust, on their £31.5 million Series A investment in Inivata Limited, a clinical cancer genomics company employing the precision of ctDNA analysis to improve personalized healthcare in oncology.
  • Giorgio Armani S.p.A. on a collaboration with a listed Dubai property company for the development of a worldwide chain of Armani hotels and resorts.
  • Merck & Co., Inc. on several global integrations and restructuring programmes.

Pro Bono

  • Advising an international charitable organization that provides micro financing to the world’s lowest-income entrepreneurs on various corporate issues.

Previous Experience

  • Secondment to the in house legal department of a global pharmaceutical company.